Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M600Revenue (TTM) $M107Net Margin (%)-89.6Altman Z-Score-10.8
Enterprise Value $M799EPS (TTM) $-0.5Operating Margin %-76.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.2Pre-tax Margin (%)-92.8Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-7.7Quick Ratio1.2Cash flow > EarningsY
Price/Sales5.65-y EBITDA Growth Rate %-24.3Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-56.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M185ROIC % (ttm)-1,383.5Gross Margin Increase y-yY

Gurus Latest Trades with AMRN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMRNGeorge Soros 2012-09-30 Sold Out -0.06%$11.17 - $15.49
($13.55)
$ 3.24-76%Sold Out0
AMRNGeorge Soros 2012-06-30 Buy 0.06%$9.47 - $14.74
($11.35)
$ 3.24-71%New holding300,000
AMRNGeorge Soros 2011-09-30 Sold Out -0.058%$8.95 - $14.82
($12)
$ 3.24-73%Sold Out0
AMRNGeorge Soros 2011-06-30 Reduce-0.04%$7.39 - $19.5
($15)
$ 3.24-78%Reduce -56.15%285,000
AMRNGeorge Soros 2011-03-31 Reduce-0.04%$7.03 - $9.33
($8.1)
$ 3.24-60%Reduce -42.66%650,000
AMRNGeorge Soros 2010-12-31 Buy 0.12%$2.49 - $8.49
($4.48)
$ 3.24-28%New holding1,133,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMRN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


AMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
THERO JOHN FPresident and CEO 2016-02-01Buy25,000$1.37136.5view
THERO JOHN FPresident and CEO 2015-08-11Buy20,000$2.3537.87view
THERO JOHN FPresident, Chief Exec. Officer 2014-11-12Buy50,000$0.83290.36view
Farrell Michael JamesController 2014-11-11Buy5,500$0.84285.71view
Southpoint Capital Advisors LP10% Owner 2006-04-20Sell0$0285.71view

Press Releases about AMRN :

Quarterly/Annual Reports about AMRN:

News about AMRN:

Articles On GuruFocus.com
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 23 2014 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Steven Cohen Adds Amarin Corp. Awaiting Drug Approval, Buys Hyatt Hotels Mar 28 2012 
Soros Funds’ Great Britain Buys and Sells Apr 13 2011 

More From Other Websites
Amarin Corporation (AMRN) Looks Good: Stock Adds 6.1% in Session Sep 27 2016
AMARIN CORP PLC\UK Files SEC form 8-K, Other Events Sep 23 2016
AMARIN CORP PLC\UK Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events,... Sep 14 2016
Raptor Pharmaceutical, Colgate-Palmolive Company & Others: Here’s Why These Stocks Are Trending... Sep 12 2016
Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation... Sep 12 2016
Amarin’s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at... Sep 12 2016
Zacks.com featured highlights: Amarin, Compugen, Raptor Pharmaceuticals, ArcelorMittal and Hovnanian... Sep 07 2016
Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference Sep 07 2016
Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference Sep 07 2016
Explosive Stocks Under $10 Sep 06 2016
8 Major FDA Decisions and Trial Results to Watch for in September Sep 02 2016
Amarin (AMRN) Ends Patient Randomization in Vascepa Study Sep 01 2016
Is Amarin Corporation Stock a Solid Choice Right Now? Aug 31 2016
Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa Aug 31 2016
Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa Aug 31 2016
ETF’s with exposure to Amarin Corp. Plc : August 29, 2016 Aug 29 2016
AMARIN CORP PLC\UK Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements... Aug 26 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)